Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qiagen ( (QGEN) ) has issued an update.
QIAGEN has reported a managers’ transaction involving CC Verwaltungs GmbH, an entity controlled by supervisory board member Dr. Colpan, in connection with the company’s recently executed synthetic share repurchase. Following the previously approved capital measure under which every 20 issued QIAGEN shares were consolidated into 19, CC Verwaltungs GmbH’s holding was adjusted by 5,282 shares to a total of 100,355 common shares, with the transaction taking place outside a trading venue on January 7, 2026; the move reflects the technical implementation of the share consolidation across insider holdings and signals continued execution of the company’s capital return program.
The most recent analyst rating on (QGEN) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a Netherlands-based life sciences company whose shares are listed on multiple European exchanges as well as the NYSE and Swiss venues. It focuses on molecular diagnostics and sample preparation technologies used in research, clinical, and applied testing markets, serving laboratories, healthcare providers, and industry customers worldwide.
Average Trading Volume: 1,155,025
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.99B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.